Clinical Trial Update: Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating enhanced platelet inhibition in critically ill COVID-19 patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corona Virus Infection
• Embolism and Thrombosis
• Pneumonia Viral
• Respiratory Failure

Snippet

Sponsor: University of Milan | Conditions: Pneumonia, Viral, Corona Virus Infection | Phase 2 | Status: COMPLETED